Is Steris (STE) overvalued or fairly valued?

MarketChacha shows Steris's valuation in context — a trailing P/E of about 30.3, a forward P/E of about 18.4, a price-to-book of about 3.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Steris's reported profit turn into cash?

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (2.24×) from reported figures — education, not a rating.

What is Steris's revenue?

Steris reported revenue of $5.9B for FY2026, with net profit of $782.3M, per official filings.

What is the share price of Steris (STE)?

Steris last traded at $225.18 (+1.4% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Steris

STE · NYSE · Healthcare · United States

Snapshot

TickerSTE

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees17,937

HeadquartersMentor, United States

Websitewww.steris.com

Filings tracked14

About Steris

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.

Who owns it

Insiders0.3%
Institutions99.7%
Public & other0.0%

1,215 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.9.05%
Vanguard Capital Management LLC6.57%
State Street Corporation5.20%
Vanguard Portfolio Management LLC5.13%
Morgan Stanley4.05%
Massachusetts Financial Services Co.3.90%
Wellington Management Group, LLP3.59%
Orbis Allan Gray Ltd2.75%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion2.24×

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend2.4% → 13.2%

Margin has expanded by about 10.8 points — the business is getting more profitable.

Growth qualityrev 9% · PAT 94%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.6B · EPS 2.80

Est. earnings growth +10.8%

Next fiscal year

Rev $6.8B · EPS 12.28

Est. earnings growth +9.9%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2026)

$5.9B

Net margin

13.2%

ROE

10.9%

Revenue CAGR (3y)

+9.4%

Profit CAGR (3y)

+94.1%

EPS (FY2026)

7.93

Net profit (FY2026)

$782.3M

Ask MarketChacha about STE

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2026	$5.9B	$782.3M	7.93	13.2%	10.9%
FY2025	$5.5B	$614.6M	6.20	11.3%	9.3%
FY2024	$5.1B	$378.2M	3.81	7.4%	6.0%
FY2023	$4.5B	$107.0M	1.07	2.4%	1.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$1.5B	$200.1M	—	13.4%
2025Q4	$1.5B	$192.9M	1.96	12.9%
2025Q3	$1.5B	$191.9M	1.94	13.1%
2025Q2	$1.4B	$177.4M	1.79	12.8%
2024Q4	$1.4B	$173.5M	1.75	12.7%
2024Q3	$1.3B	$150.0M	1.51	11.3%
2024Q2	$1.3B	$145.4M	1.46	11.4%
2024Q1	$1.4B	$-1.4M	-0.01	-0.1%
2023Q4	$1.3B	$140.7M	1.42	10.8%
2023Q3	$1.2B	$115.3M	1.16	9.3%
2023Q2	$1.2B	$123.6M	1.25	10.4%
2023Q1	$1.3B	$187.2M	1.88	14.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/7/2026
8-K/A — Executive/director change
SEC8/6/2026
8-K — Shareholder vote results
SEC8/6/2026material
8-K — Results of operations, Costs from exit/disposal, Exhibits
SEC8/5/2026material
10-K filing
SEC5/29/2026
8-K — Results of operations, Exhibits
SEC5/11/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC5/7/2026material
8-K — Executive/director change
SEC4/6/2026material
10-Q filing
SEC2/6/2026
8-K — Results of operations, Exhibits
SEC2/4/2026material

2025

10-Q filing
SEC11/6/2025
8-K — Results of operations, Exhibits
SEC11/5/2025material
10-Q filing
SEC8/7/2025
8-K — Results of operations, Executive/director change, Shareholder vote results, Exhibits
SEC8/6/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.